With respect to in vivo therapeutic applications of Cas9, Gillmore et al. [97] reported delivery of intravenous injections of mRNA encoding Cas9 and a gRNA targeting the transthyretin gene encapsulated in lipid nanoparticles in six patients with life-threatening transthyretin amyloidosis. This evidence concerns the gene TTR and amyloidosis.